Jacobio plans Hong Kong IPO
Beijing-based drug company Jacobio Pharma is eyeing an IPO on the Hong Kong stock exchange later this year, Bloomberg reported, citing people familiar with the situation.
The Chinese biotech could raise $400 million through the offering, sources said. The company was founded in 2015 and has focused on developing cancer therapies, drawing funding from top-tiered private equity investment companies such as Qiming Venture Partners, Hillhouse Capital, and Lilly Asia Ventures.
The global pandemic has not deterred investors from deploying capital toward health care IPOs. The Hong Kong Stock Exchange has seen a steady stream of biotech and health care companies going public this year, raising nearly $4.5 billion, which is almost as much as last year’s total, according to Bloomberg data.
The Chinese biotech could raise $400 million through the offering, sources said. The company was founded in 2015 and has focused on developing cancer therapies, drawing funding from top-tiered private equity investment companies such as Qiming Venture Partners, Hillhouse Capital, and Lilly Asia Ventures.
The global pandemic has not deterred investors from deploying capital toward health care IPOs. The Hong Kong Stock Exchange has seen a steady stream of biotech and health care companies going public this year, raising nearly $4.5 billion, which is almost as much as last year’s total, according to Bloomberg data.
.png)
No hay comentarios:
Publicar un comentario